Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population

Cantara, Silvia; Pilli, Tania; Sebastiani, Guido; Cevenini, Gabriele; Busonero, Giulia; Cardinale, Sandro; Dotta, Francesco; Pacini, Furio

doi:10.1210/jc.2014-1923

Cited by 54 publications

(50 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cantara et al reported that circulating miRNA95 and miRNA190 were sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population (MiRNA95 had a sensitivity of 94.9% which reached 100% in a multivariate risk model combined with miRNA190) [10]. Lee et al identified that tumor levels of miR-222 and miR-146b are associated with PTC recurrence and that miR-222 and miR-146b levels in the circulation correspond to the presence of PTC [11].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, several authors [10][11][12] have reported that circulating miRNAs may have potential utility as diagnostic or prognostic markers for thyroid cancers. But to the best of our knowledge, circulating miRNA profiles between non-131 I-avid and 131 I-avid lung metastases form papillary thyroid carcinoma have not been analyzed.…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

See 1 more Smart Citation

Differential expression profiling of circulation microRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases: a pilot study

Qiu

Shen

Song

et al. 2015

Nuclear Medicine and Biology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

Differential expression profiling of circulation microRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases: a pilot study

Qiu

Shen

Song

et al. 2015

Nuclear Medicine and Biology

View full text Add to dashboard Cite

“…They also found that miR-146b, miR-155 and miR-222 were slightly higher in patients with lymph node metastasis than in patients without lymph node involvement [80]. The third study identified miR-579, miR-95, miR-29b as being downregulated and miR-190 upregulated in serum of PTC patients compared to patients with nodular goiter (NG) and healthy controls [81]. By combining expression data of miR-95 and miR-190, the authors developed a multivariate risk model which was able to differentiate PTC samples from NGs with 0.99 AUC [81].…”

Section: Endocrine Tumorsmentioning

confidence: 94%

“…The third study identified miR-579, miR-95, miR-29b as being downregulated and miR-190 upregulated in serum of PTC patients compared to patients with nodular goiter (NG) and healthy controls [81]. By combining expression data of miR-95 and miR-190, the authors developed a multivariate risk model which was able to differentiate PTC samples from NGs with 0.99 AUC [81]. In addition, miR-579 and miR-95 were significantly downregulated in PTC compared with NG, while miR-190 was upregulated in PTC both at tissue level and in serum samples.…”

Section: Endocrine Tumorsmentioning

confidence: 99%

Circulating miRNAs as biomarkers for endocrine disorders

Butz

Kinga

Rácz

et al. 2015

J Endocrinol Invest

View full text Add to dashboard Cite

Specific, sensitive and non-invasive biomarkers are always needed in endocrine disorders. miRNAs are short, non-coding RNA molecules with well-known role in gene expression regulation. They are frequently dysregulated in metabolic and endocrine diseases. Recently it has been shown that they are secreted into biofluids by nearly all kind of cell types. As they can be taken up by other cells they may have a role in a new kind of paracrine, cell-to-cell communication. Circulating miRNAs are protected by RNA-binding proteins or microvesicles hence they can be attractive candidates as diagnostic or prognostic biomarkers. In this review, we summarize the characteristics of extracellular miRNA's and our knowledge about their origin and potential roles in endocrine and metabolic diseases. Discussions about the technical challenges occurring during identification and measurement of extracellular miRNAs and future perspectives about their roles are also highlighted.

show abstract

“…Kaukázusi népes-ségben ugyanakkor a miR-190 felül-, illetve a miR-95 alulexpresszálódott egészséges emberekhez és jóindulatú elváltozásokhoz viszonyítva [20]. Egy újabb tanulmány-ban a PTC-s betegeket is két csoportra osztották nyirokcsomóáttét megléte alapján.…”

Section: Táblázatunclassified

Keringő mikroRNS-ek az endokrin daganatok diagnosztikájában

et al. 2017

View full text Add to dashboard Cite

A mikroRNS-ek (miRNS, miR) rövid -19-25 nukleotidból álló -érett formájukban egyszálú, nem kódoló RNSmolekulák, amelyek a génexpressziót főként poszttranszkripcionális szinten befolyásolják. A mikroRNS-ek szerepet játszanak élettani folyamatokban, például a sejtdifferenciálódás és -proliferáció szabályozásában, egyedfejlődésben, vérképzésben, sejthalálban, míg aberráns expressziójuk számos betegség, köztük autoimmun betegségek, gyulladá-sok, vascularis betegségek vagy daganatok kialakulása során megfigyelhető. A mikroRNS-ek szövetspecifikus módon fejeződnek ki. Szöveti megjelenésük mellett különböző testfolyadékokban is megtalálhatóak. Így például a vérben, az anyatejben, az ondóban, nyálban, vizeletben stb. A testfolyadékokban megjelenő mikroRNS-ek, így különösen a vér keringő mikroRNS-ei, a daganatok kórisméjében mint minimálisan invazív diagnosztikai eszközök jöhetnek szóba. Az endokrin daganatokra jellemző leírt keringő mikroRNS-kifejeződések száma eddig alacsony, főként a papillaris pajzsmirigy-carcinomára, mellékvesekéreg-carcinomára, petefészekrákra, illetve egyes neuroendokrin tumorokra szorítkozik. Tekintettel arra, hogy e daganatok egy részének szövettani diagnózisa, a malignitás megállapítása nehéz, a keringő mikroRNS-ek kutatásában jelentős távlatok rejlenek. Orv. Hetil., 2017, 158(13), 483-490.Kulcsszavak: mikroRNS, daganat-biomarker, pajzsmirigydaganat, mellékvesekéreg-carcinoma, petefészek-daganat Circulating microRNAs in the diagnostics of endocrine neoplasmsMicroRNAs (miRNA, miR) are short -19-25 nucleotide long -single stranded (in their mature form), non-coding RNA molecules that regulate gene expression mostly at the posttranscriptional level. microRNAs are involved in the regulation of various physiological processes such as cell differentiation and proliferation, development, haematopoesis, cell death, while their aberrant expression is observed in numerous diseases, like autoimmune disorders, inflammations, vascular diseases or tumorigenesis. microRNAs are expressed in a tissue specific fashion. Beyond their appearance in tissues, they can be found in body fluids as well. microRNAs are present in blood, mother milk, semen, saliva, urine, etc. MicroRNAs in body fluids, especially the blood-borne circulating microRNAs can be exploited as minimally invasive biomarkers of tumor diagnosis. The number of endocrine tumor-associated circulating microRNA alterations is relatively low, mostly described for papillary thyroid cancer, adrenocortical cancer, ovarian and neuroendocrine tumors. As the histological diagnosis including the establishment of malignancy of some of these neoplasms is difficult, studies on circulating microRNAs might have great perspectives.Keywords: microRNA, tumor biomarker, thyroid neoplasm, adrenocortical carcinoma, ovarian neoplasm Decmann, Á., Perge, P., Nagy, Z., Butz, H., Patócs, A., Igaz, P. [Circulating microRNAs in the diagnostics of endocrine neoplasms]. Orv. Hetil., 2017, 158(13), 483-490. (Beérkezett: 2017 elfogadva: 2017. február ÖSSZEFOGLALÓ KÖZLEMÉNYRövidí...

show abstract

Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population

Cited by 54 publications

References 20 publications

Differential expression profiling of circulation microRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases: a pilot study

Differential expression profiling of circulation microRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases: a pilot study

Circulating miRNAs as biomarkers for endocrine disorders

Keringő mikroRNS-ek az endokrin daganatok diagnosztikájában

Contact Info

Product

Resources

About